Thrombotic thrombocytopenic purpura associated with adalimumab (Humira) treatment in Crohn disease

摘要

This is a case of a patient who developed thrombotic thrombocytopenic purpura (TTP) during her treatment with adalimumab (Humira) for Crohn disease. There is no prior documentation of such cases. However, there are rare reports of cytopenias with adalimumab.1 A 44-year-old woman who presented with a 4-day history of nausea and bile-stained vomiting after her fourth dose of fortnightly adalimumab for Crohn disease.